SS-31 (Elamipretide) Peptide: Dubai Research Vial COA & Purity
SS-31 — also sold under the name elamipretide — is one of the most-studied mitochondrial-targeted peptides, which is exactly why careful sourcing matters. The sections below cover identity, COA verification, and where the evidence stops — research-use framing throughout.
Update History ▾
July 10, 2026: Corrected the TAZPOWER publication citation and refreshed the MOTS-c cross-reference.
June 8, 2026: Initial publication, drawing on the Remy SS-31 research profile and peer-reviewed and official sources.
Research-use-only framing applied throughout in line with Remy editorial standards.
SS-31 (elamipretide) is a cardiolipin-targeting mitochondrial tetrapeptide with one of the deepest research datasets in its class — so the material-verification question really comes down to confirmed identity and purity, not hype. The compound is a 10mg lyophilized research vial format in laboratory use, and the closest mechanistic neighbour is MOTS-c, a mitochondrial-DNA-encoded peptide that works through a different pathway. The sections below cover identity, COA verification, and where the evidence stops — research-use framing throughout.
Verifying SS-31 identity first
SS-31 appears under several names — you will see it written as SS31, as elamipretide, and in older literature as Bendavia or MTP-131 — so the first job of any material check is confirming that the vial in front of you is the same molecule. The sections below walk through that identity check, how to confirm HPLC purity and compound identity, what the published research does and does not establish, and how researchers in Dubai and the UAE can document the provenance of an SS-31 vial.
For the full cardiolipin-binding mechanism and trial dataset, read the SS-31 mitochondrial peptide research profile. For the analytical methodology behind a purity claim, see the peptide COA and HPLC purity guide.
Compound Identity: What SS-31 Actually Is
SS-31 is the Szeto-Schiller designation for a synthetic aromatic-cationic tetrapeptide, also known by the clinical development name elamipretide and the earlier investigational names Bendavia and MTP-131. The sequence is D-Arg-2’6’-Dmt-Lys-Phe-NH2, with molecular formula C32H49N9O5 and a molecular weight of approximately 639.8 g/mol.
What makes SS-31 distinct as a research compound is its target. Rather than relying on the mitochondrial membrane potential to drive accumulation in the matrix, SS-31 concentrates at the inner mitochondrial membrane and binds cardiolipin — the anionic phospholipid that organises electron transport chain complexes at cristae junctions. Birk et al. (2013, J Am Soc Nephrol) characterised this dual-mode binding (electrostatic anchoring via the cationic residues plus hydrophobic insertion of the aromatic side chains) by NMR.[1] For any record, the practical point is narrower: material that calls itself SS-31 should match this identity exactly, because elamipretide is a specific tetrapeptide, not a loose category. Identity precision is the first line of the COA check below.
Evidence Map and Translation Limits
SS-31 carries the broadest clinical dataset of any mitochondria-targeted research peptide, which makes the translation discipline more important, not less. The aging skeletal-muscle crossover study (Siegel et al., PNAS 2021) reported improved mitochondrial ATP production after a single infusion in older adults,[2] and the TAZPOWER Phase 2 trial in Barth syndrome reported a meaningful 6-minute-walk signal.[3] Those records describe a regulated drug program in defined patient populations — they do not convert a research-use vial into a clinical product or support any consumer outcome claim.[4]
| Research layer | What the literature supports | What it means for sourcing |
|---|---|---|
| Identity | SS-31, elamipretide, Bendavia and MTP-131 name the same tetrapeptide (D-Arg-Dmt-Lys-Phe-NH2). | A record and COA should match this exact identity — that is how you rule out an alias mix-up. |
| Mechanism | Cardiolipin binding at the inner membrane is well characterised in cell and isolated-mitochondria models. | Explains how SS-31 behaves in cell and mitochondria models — not a basis for any outcome claim. |
| Evidence tier | Strongest human signals are Phase 2 RCTs (Barth syndrome) and small crossover work (aging muscle); most indications remain hypothesis-generating. | Treat the human data as early-stage; most uses remain hypothesis-generating. |
| Documentation in the UAE | Local researchers need compound identity, vial size, format, and a verifiable COA route. | Confirm vial size, format, and the HPLC purity line standard against the analytical record. |
Dubai/UAE Reference Record
The table below records the stable material facts researchers ask about when documenting an SS-31 vial in a UAE laboratory.
| Field | Reference record |
|---|---|
| Compound | SS-31 / elamipretide (also Bendavia, MTP-131) |
| Sequence | D-Arg-2’6’-Dmt-Lys-Phe-NH2 |
| Format | 10mg · Lyophilized research vial |
| Purity reference | >99% HPLC line standard for in-vitro research |
| COA route | Archived analytical records are indexed in the COA library, which publishes Janoshik batch reports across the Retatrutide range. |
| Use restriction | For in-vitro laboratory research only. Not for human or veterinary use. |
COA and Purity Checks for Laboratory Records
For Dubai and UAE laboratories, the cleanest documentation checklist for SS-31 is identity-first and verification-heavy. Before logging any SS-31 10mg material, confirm:
- The documentation names the compound precisely — SS-31 / elamipretide, sequence D-Arg-Dmt-Lys-Phe-NH2 — and records vial size and format.
- The record states the >99% HPLC line standard and an identity method (mass spec) for the compound.
- The record states Research Use Only and avoids human-use, veterinary-use, diagnostic, therapeutic, or disease-management claims.
- Cold-storage handling and official-contact verification are documented well enough to reduce impersonation and gray-market risk for a lyophilized peptide.
That verification workflow runs through the COA library and contact verification. For the analytical methodology behind a purity figure, see the peptide COA and HPLC purity guide. For the regulatory framing that applies to research peptides locally, see Are research peptides legal in the UAE?
What This Page Does Not Claim
The research record helps define the compound, but it does not turn an RUO vial into a clinical product. Keep these boundaries in view:
- Avoid anti-aging, energy, athletic-performance, or organ-protection promises for any individual.
- Do not provide human-use instructions, dosing, or protocols.
- Do not imply that the Phase 2 trial program or the 2025 Forzinity (elamipretide HCl) approval for Barth syndrome makes a research-use vial a treatment for any condition.
Our Research Standards
This guide draws on the Remy SS-31 mitochondrial research profile and peer-reviewed and official (FDA, journal) sources. No therapeutic, human-use, or veterinary-use claim is made. Read our editorial policy →
SS-31 10mg Research FAQ
What exactly is SS-31, and what other names does it appear under?
SS-31 is the Szeto-Schiller designation for a synthetic aromatic-cationic tetrapeptide, sequence D-Arg-2'6'-Dmt-Lys-Phe-NH2, molecular formula C32H49N9O5, molecular weight approximately 639.8 g/mol. It is also published as elamipretide and, in earlier literature, as Bendavia and MTP-131. Any record that calls itself SS-31 should match that identity exactly.
What format is SS-31 supplied in for laboratory research?
The standard research format is a 10mg lyophilized vial. Format, purity method, and storage conditions are the material facts worth recording; see the peptide stability and storage guide for handling context.
How should a researcher verify the COA and purity of an SS-31 vial?
Confirm the documentation states the compound identity (SS-31 / elamipretide, sequence D-Arg-Dmt-Lys-Phe-NH2) and the HPLC purity standard recorded for the vial. SS-31 is referenced against a >99% HPLC line standard for in-vitro research; published Janoshik COAs across the Retatrutide range are indexed in the COA library.
Is SS-31 10mg intended for human or veterinary use?
No. SS-31 research material is for in-vitro laboratory research only. It is not for human use, veterinary use, diagnosis, treatment, cure, disease management, or personal-use protocols.
Which page should researchers read next?
Read the SS-31 mitochondrial peptide research profile for the full cardiolipin-binding mechanism and trial-evidence context, and the peptide COA and HPLC purity guide for the analytical methodology behind a purity figure.
Sources
- Birk AV, Liu S, Soong Y, et al. The mitochondrial-targeted compound SS-31 re-energizes ischemic mitochondria by interacting with cardiolipin. J Am Soc Nephrol. 2013;24(8):1250–1261. PMID: 23813215 ↑
- Roshanravan B, Liu SZ, et al. In vivo mitochondrial ATP production is improved in older adult skeletal muscle after a single treatment with elamipretide. PLOS ONE. 2021;16(7):e0253849. PMID: 34264994 ↑
- Reid Thompson W, Hornby B, et al. A phase 2/3 randomized clinical trial followed by an open-label extension to evaluate the effectiveness of elamipretide in Barth syndrome. Genet Med. 2021;23(3):471–478. PMID: 33077895 ↑
- U.S. Food and Drug Administration. FDA grants accelerated approval for first treatment for Barth syndrome. 2025. fda.gov ↑
For the archived analytical route, use the COA library. For the full mechanism and trial dataset, continue to the SS-31 mitochondrial peptide research profile and official contact verification.